Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30%)of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.
Support Care Cancer
August 2025
Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Purpose: Conditioning with high-dose melphalan (MEL) followed by autologous stem cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM). The optimal regimen to prevent chemotherapy-induced nausea and vomiting (CINV) is unclear. We aimed to retrospectively evaluate the antiemetic effect and safety of a four-drug intensive regimen including olanzapine (OLA) on CINV in MM patients receiving MEL/ASCT.
View Article and Find Full Text PDFAprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen - Role in Effectiveness of Prevention of Nausea and Vomiting.
Acta Med Litu
February 2025
Department of Pharmacology, AIIMS Guwahati, Changsari, Assam, India.
Background: Chemotherapy-induced nausea and vomiting (CINV) is a significant concern for patients undergoing highly emetogenic chemotherapy (HEC). This study compares the efficacy of aprepitant and olanzapine in preventing CINV in breast cancer patients receiving Adriamycin and Cyclophosphamide (AC).
Methods: A prospective, comparative, observational study was conducted over one year at the State Cancer Institute, Guwahati, India.
Systemic neurokinin-1 receptor antagonists mitigate chronic pruritus: A systematic review and meta-analysis.
J Eur Acad Dermatol Venereol
June 2025
Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Evidence suggests that substance P and neurokinin-1 receptor (NK1R) are often overexpressed in various chronic pruritus-inducing conditions. Several randomized controlled trials (RCTs) have demonstrated that targeting NK1R disrupts key itch signalling pathways, indicating the antipruritic effects of NK1R antagonists. However, these results remain to be validated.
View Article and Find Full Text PDFOverall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Oncol
July 2025
Clinical Research and Trial Centre, Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan.
Background: The addition of 10 mg olanzapine to the standard triplet antiemetic therapy has shown superiority in controlling chemotherapy-induced nausea and vomiting compared with triplet therapy alone for highly emetogenic chemotherapy, albeit with sedative side-effects. We aimed to investigate if administering 5 mg of olanzapine at home after anthracycline plus cyclophosphamide chemotherapy, rather than before chemotherapy, can maintain efficacy in controlling chemotherapy-induced nausea and vomiting while minimising sedative side-effects and associated risks.
Methods: This was a phase 3, double-blind, randomised, placebo-controlled trial, done in 15 hospitals and cancer centres in Japan.
Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study.
Support Care Cancer
May 2025
Department of Oncology, Odense University Hospital, Odense, Denmark.
Purpose: Netupitant 300 mg/palonosetron 0.5 mg (NEPA) would be ideal as antiemetic prophylaxis for patients receiving weekly cisplatin, as it would reduce concurrent medication intake compared to the 3-day aprepitant regimen. However, due to the longer half-life of netupitant (~ 88 h), weekly administration could potentially lead to accumulation and toxicity.
View Article and Find Full Text PDF